Pathogen reduction/inactivation of products for the treatment of bleeding disorders: what are the processes and what should we say to patients?
Crossref DOI link: https://doi.org/10.1007/s00277-017-3028-4
Published Online: 2017-06-18
Published Print: 2017-08
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Di Minno, Giovanni
Navarro, David
Perno, Carlo Federico
Canaro, Mariana
Gürtler, Lutz
Ironside, James W.
Eichler, Hermann
Tiede, Andreas
Funding for this research was provided by:
Pfizer UK (N/A)
License valid from 2017-06-18